Development of New Geographic Atrophy in Patients With Neovascular (Wet) Age-related Macular Degeneration: a Comparison of Ranibizumab and Aflibercept
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Dry macular degeneration; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RIVAL
- Sponsors Novartis; Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 06 Dec 2017 Status changed from active, no longer recruiting to completed.
- 05 Oct 2017 Status changed from recruiting to active, no longer recruiting.